These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 21503556)

  • 1. Procurement of generic medicines in a medium size municipality.
    Bevilacqua G; Farias MR; Blatt CR
    Rev Saude Publica; 2011 Jun; 45(3):583-9. PubMed ID: 21503556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflated medicine prices in Vietnam: a qualitative study.
    Nguyen TA; Knight R; Mant A; Razee H; Brooks G; Dang TH; Roughead EE
    Health Policy Plan; 2017 Jun; 32(5):647-656. PubMed ID: 28453716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Municipal consortia for medicine procurement: impact on the stock-out and budget.
    Amaral SM; Blatt CR
    Rev Saude Publica; 2011 Aug; 45(4):799-801. PubMed ID: 21445459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perceptions and utilization of generic medicines in Guatemala: a mixed-methods study with physicians and pharmacy staff.
    Flood D; Mathieu I; Chary A; García P; Rohloff P
    BMC Health Serv Res; 2017 Jan; 17(1):27. PubMed ID: 28086866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investment of financial resources for the procurement of medicines for primary care in Brazilian municipalities.
    Pontes MA; Tavares NUL; Francisco PMSB; Naves JOS
    Cien Saude Colet; 2017 Aug; 22(8):2453-2462. PubMed ID: 28793063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The crisis in access to essential medicines in India: key issues which call for action.
    Bhargava A; Kalantri SP
    Indian J Med Ethics; 2013; 10(2):86-95. PubMed ID: 23697486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmaceutical services in Rio de Janeiro Municipality, Brazil: development regarding selected aspects from 2008 to 2014.
    Silva RM; Pereira NC; Mendes LV; Luiza VL
    Cien Saude Colet; 2016 May; 21(5):1421-32. PubMed ID: 27166892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Demand-side policies to encourage the use of generic medicines: an overview.
    Dylst P; Vulto A; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2013 Feb; 13(1):59-72. PubMed ID: 23402447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A survey exploring knowledge and perceptions of general practitioners towards the use of generic medicines in the northern state of Malaysia.
    Chua GN; Hassali MA; Shafie AA; Awaisu A
    Health Policy; 2010 May; 95(2-3):229-35. PubMed ID: 20044165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis.
    Cameron A; Ewen M; Ross-Degnan D; Ball D; Laing R
    Lancet; 2009 Jan; 373(9659):240-9. PubMed ID: 19042012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retailing policies for generic medicines.
    Narciso S
    Int J Health Care Finance Econ; 2005 Jun; 5(2):165-90. PubMed ID: 15912315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of price deregulation policy on the affordability of essential medicines for women's health: a panel data analysis.
    Liu J; Wang L; Liu C; Zhang X
    Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):625-631. PubMed ID: 28503962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Judicialization of medicines: effectiveness of rights or break in public policies?
    Oliveira YMDC; Braga BSF; Farias AD; Pereira SPD; Ferreira MAF
    Rev Saude Publica; 2020; 54():130. PubMed ID: 33331524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved?
    Cameron A; Mantel-Teeuwisse AK; Leufkens HG; Laing RO
    Value Health; 2012; 15(5):664-73. PubMed ID: 22867775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pricing and components analysis of some key essential pediatric medicine in Odisha state.
    Samal S; Swain TR
    Indian J Pharmacol; 2017; 49(1):89-92. PubMed ID: 28458429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation on the need of multiple dose bioequivalence studies for prolonged-release generic products.
    García-Arieta A; Morales-Alcelay S; Herranz M; de la Torre-Alvarado JM; Blázquez-Pérez A; Suárez-Gea ML; Alvarez C
    Int J Pharm; 2012 Feb; 423(2):321-5. PubMed ID: 22120644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Price differences between generic and innovator medicines in Brazil].
    Vieira FS; Zucchi P
    Rev Saude Publica; 2006 Jun; 40(3):444-9. PubMed ID: 16810368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bioequivalence studies of pharmaceutical preparations].
    Vetchý D; Frýbortová K; Rabisková M; Danecková H
    Cas Lek Cesk; 2007; 146(5):431-3. PubMed ID: 17554963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
    't Hoen E
    Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.